摘要
目的观察秋水仙碱联合依托芬那酯凝胶对急性痛风性关节炎患者的临床疗效及安全性。方法将2013年6月-2014年7月收治的150例急性痛风性关节炎患者随机分为A、B、C组,每组各50例。A组采用秋水仙碱、B组采用秋水仙碱+依托芬那酯凝胶、C组采用秋水仙碱+依托考昔进行治疗。对3组患者治疗前后关节疼痛、触痛、健康质量评估和患者与研究者对总体疗效的评价进行比较。结果 A、B、C组因不良事件分别脱落2、3、7例,故实际完成试验的患者为:A组48例,B组47例,C组43例。3组患者经7 d治疗后疼痛的主客观评估均有明显缓解,但组间比较差异无统计学意义(P>0.05)。对疗效的主观评估中,B组患者评分最高,优于A、C组,差异有统计学意义(P=0.012、0.025)。而对疗效的客观评估则3组间差异无统计学意义(F=0.021,P=0.908)。对关节肿胀的评估则是C组改善优于A、B组,差异有统计学意义(P=0.041、0.034)。3组患者健康质量评估量表评估结果相似。研究结束时3组中C反应蛋白和红细胞沉降率都有下降,但仅A、C组组间比较差异有统计学意义(P<0.05)。不良事件发生率在C组最高,差异有统计学意义(P<0.05)。结论秋水仙碱联合依托芬那酯凝胶治疗急性痛风性关节炎的疗效与秋水仙碱联合依托考昔相当,但安全性更好。
Objective To observe the efficacy and safety of colchicine combined with etofenamate cream in the treatment of acute gouty arthritis. Methods A total of 150 patients diagnosed with acute gouty arthritis from June 2013 to July 2014 were equally randomized to receive colchicine alone（group A）, colchicine with etofenamate cream（group B） and colchicine with etoricoxib（group C）. The assessment on joint pain, tenderness, health quality and clinical efficacy of patients in each group was carried out, and the results were compared before and 7 days after the treatment. Results Because of adverse events, the number of patients who withdrew from group A, B and C was respectively 2, 3 and 7. So the actual number of patients completing the study was 48 for group A, 47 for group B and 43 for group C. The patients＇ and physicians＇ assessments of mean change in pain intensity from baseline over days 1-7 were comparable in each group, with no statistical significance between groups（P〈0.05）. The patients＇ assessment of response to treatment was the highest in the colchicine with etofenamate cream group, and the differences compared with other two groups were significant（P=0.012 and 0.025, respectively）. The physicians＇ global assessment of response to treatment showed no statistical significance between groups（F=0.021, P=0.908）. The joint tenderness was most improved in colchicine with etoricoxib group, and the differences compared with other two groups were significant（P=0.041 and 0.034, respectively）. The assessments of health quality were similar between groups. The C-reactive protein and erythrocyte sedimentation rate were decreased at study-end in all groups, but statistically significant differences were only found between group A and C（P〈0.05）. The incidence rate of adverse events was the highest in colchicine with etoricoxib group and the difference from other two groups was significant（P〈0.05）. Conclusion Colchicine with etofenamate cream is as effective as colchicine with etoricoxib for treating acute gout and may have a better safety and tolerability profile.
出处
《华西医学》
CAS
2016年第3期487-490,共4页
West China Medical Journal
